GoAI
Get started
Hangzhou Tigermed Consulting Co., Ltd logo

Hangzhou Tigermed Consulting Co., Ltd

3347.HK

HKSEHealthcareBiotechnology

Open in GoAI

Latest quote

HK$38.10

−HK$1.90 · -4.75%

Aug 24, 1:48 PM HKT

3347.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical trials, registration and declaration of clinical trials, on-site services, as well as data management and analysis, etc. The company was founded on December 15, 2004 and is headquartered in Hangzhou, China.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CN
CEO
Xiao Chun Cao
Listed since
Aug 7, 2020
Employees
11,130

Market position

Day range

Current HK$38.10

52-week range

Current HK$38.10

Open
HK$40.06
Previous close
HK$40.00
Volume
941.7K
0.46× average
Average volume
2.03M
Average daily volume
Market cap
46.25B HKD
Beta
0.34
Market reference 1
50-day average
HK$36.7672
+3.62% above average
200-day average
HK$41.1287
-7.36% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
32.6B CNY
EV / EBITDA
22.95×
Earnings yield
2.70%
Free cash flow yield
2.75%

Profitability & efficiency

Return on equity
4.24%
Return on assets
3.13%
Return on invested capital
3.11%

Financial health

Current ratio
2.18×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends60%40%21%1%Gross margin, FY2021: 43.55%Gross margin, FY2022: 39.64%Gross margin, FY2023: 38.58%Gross margin, FY2024: 33.95%Gross margin, FY2025: 27.41%Operating margin, FY2021: 36.81%Operating margin, FY2022: 36.45%Operating margin, FY2023: 33.68%Operating margin, FY2024: 10.06%Operating margin, FY2025: 14.77%Net margin, FY2021: 55.13%Net margin, FY2022: 28.32%Net margin, FY2023: 27.42%Net margin, FY2024: 6.14%Net margin, FY2025: 12.99%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 43.55%. Gross margin FY2022 39.64%. Gross margin FY2023 38.58%. Gross margin FY2024 33.95%. Gross margin FY2025 27.41%. Operating margin FY2021 36.81%. Operating margin FY2022 36.45%. Operating margin FY2023 33.68%. Operating margin FY2024 10.06%. Operating margin FY2025 14.77%. Net margin FY2021 55.13%. Net margin FY2022 28.32%. Net margin FY2023 27.42%. Net margin FY2024 6.14%. Net margin FY2025 12.99%.

Income trends

Revenue

6.83B CNY+3.48%

Operating income

1.01B CNY+51.93%

Net income

887.89M CNY+119.15%
Income trends across reported periods8.08B CNY5.29B CNY2.5B CNY−292.75M CNYRevenue, FY2021: 5.21B CNYRevenue, FY2022: 7.09B CNYRevenue, FY2023: 7.38B CNYRevenue, FY2024: 6.6B CNYRevenue, FY2025: 6.83B CNYOperating income, FY2021: 1.92B CNYOperating income, FY2022: 2.58B CNYOperating income, FY2023: 2.49B CNYOperating income, FY2024: 664.42M CNYOperating income, FY2025: 1.01B CNYNet income, FY2021: 2.87B CNYNet income, FY2022: 2.01B CNYNet income, FY2023: 2.02B CNYNet income, FY2024: 405.14M CNYNet income, FY2025: 887.89M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 5.21B CNY. Revenue FY2022 7.09B CNY. Revenue FY2023 7.38B CNY. Revenue FY2024 6.6B CNY. Revenue FY2025 6.83B CNY. Operating income FY2021 1.92B CNY. Operating income FY2022 2.58B CNY. Operating income FY2023 2.49B CNY. Operating income FY2024 664.42M CNY. Operating income FY2025 1.01B CNY. Net income FY2021 2.87B CNY. Net income FY2022 2.01B CNY. Net income FY2023 2.02B CNY. Net income FY2024 405.14M CNY. Net income FY2025 887.89M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue6.83B CNY6.6B CNY7.38B CNY7.09B CNY5.21B CNY
Cost of goods sold4.96B CNY4.36B CNY4.54B CNY4.28B CNY2.94B CNY
Gross profit1.87B CNY2.24B CNY2.85B CNY2.81B CNY2.27B CNY
Research and development257.64M CNY238.39M CNY261.56M CNY234.62M CNY211.83M CNY
Selling, general, and administrative322.2M CNY349.25M CNY306.72M CNY405.95M CNY373.42M CNY
Operating expenses863.77M CNY1.58B CNY361.59M CNY997.69M CNY892.77M CNY
Interest income15.13M CNY90.22M CNY229.85M CNY227.34M CNY255.88M CNY
Interest expense90.56M CNY141.24M CNY119.9M CNY83.18M CNY24.91M CNY
Depreciation and amortization326.67M CNY324.14M CNY305.69M CNY264.75M CNY188.92M CNY
Operating income1.01B CNY664.42M CNY2.49B CNY2.58B CNY1.92B CNY
Net income887.89M CNY405.14M CNY2.02B CNY2.01B CNY2.87B CNY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
18%
2 beats, 9 misses, 0 met estimates
Average EPS surprise
-44.20%
11 comparable reports
Latest EPS result
0.07
Estimate 0.27 · Miss by 74.88%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.910.41-0.1-0.61Q4 '24MissQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26Estimate
Q4 2024, reported Oct 29, 2024: actual 0.37, estimate 0.59, surprise -37.29%, Miss. Q1 2025, reported Mar 26, 2025: actual -0.503, estimate 0.66, surprise -176.26%, Miss. Q2 2025, reported Apr 28, 2025: actual 0.203, estimate 0.394, surprise -48.55%, Miss. Q3 2025, reported Aug 28, 2025: actual 0.274, estimate 0.382, surprise -28.29%, Miss. Q4 2025, reported Oct 28, 2025: actual 0.808, estimate 0.345, surprise +134.07%, Beat. Q1 2026, reported Mar 30, 2026: actual -0.174, estimate -0.079, surprise -120.55%, Miss. Q2 2026, reported Apr 28, 2026: actual 0.069, estimate 0.274, surprise -74.88%, Miss. Q3 2026, reported Aug 28, 2026: actual —, estimate 0.311, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.33B2.07B1.81B1.54BQ4 '24MissQ1 '25MissQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26Estimate
Q4 2024, reported Oct 29, 2024: actual 1.89B HKD, estimate 2.24B HKD, surprise -15.55%, Miss. Q1 2025, reported Mar 26, 2025: actual 1.63B HKD, estimate 1.69B HKD, surprise -3.45%, Miss. Q2 2025, reported Apr 28, 2025: actual 1.67B HKD, estimate 1.85B HKD, surprise -10.00%, Miss. Q3 2025, reported Aug 28, 2025: actual 1.84B HKD, estimate 1.75B HKD, surprise +5.38%, Beat. Q4 2025, reported Oct 28, 2025: actual 1.94B HKD, estimate 1.95B HKD, surprise -0.72%, Miss. Q1 2026, reported Mar 30, 2026: actual 2.05B HKD, estimate 2.21B HKD, surprise -7.31%, Miss. Q2 2026, reported Apr 28, 2026: actual 2.07B HKD, estimate 2.05B HKD, surprise +0.95%, Beat. Q3 2026, reported Aug 28, 2026: actual —, estimate 2.17B HKD, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.3245

2025 complete year-10.3% since 2021

2026 partial: HK$0.1447

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jun 18, 2026

HK$0.1447

Annual

Record Jun 22, 2026 · Payment Jul 22, 2026

Dividend

Ex-dividend Jun 12, 2025

HK$0.3245

Annual

Record Jun 13, 2025 · Payment Jul 11, 2025

Dividend

Ex-dividend Jun 7, 2024

HK$0.6237

Annual

Record Jun 11, 2024 · Payment Jul 18, 2024

Dividend

Ex-dividend May 25, 2023

HK$0.6156

Annual

Record May 29, 2023 · Payment Jul 7, 2023

Dividend

Ex-dividend May 24, 2022

HK$0.5796

Annual

Record May 25, 2022 · Payment Jun 20, 2022

Dividend

Ex-dividend May 25, 2021

HK$0.3619

Annual

Record May 26, 2021 · Payment Jun 21, 2021

3347.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.8

-3.89%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.74

-3.03%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$222.4

-2.46%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.22

-5.62%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.2

-2.15%

ETFs holding 3347.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard FTSE Emerging Markets ETF logoVanguard FTSE Emerging Markets ETFVWO
Market value
8.75M
Weight
0.01%
AUM
162.3B USD
Expense ratio
0.06%
Price / 1D
$60.45+0.72%
Vanguard Total International Stock ETF logoVanguard Total International Stock ETFVXUS
Market value
8.53M
Weight
0.00%
AUM
646.2B USD
Expense ratio
0.05%
Price / 1D
$87.71+0.78%
Vanguard FTSE All-World ex-US ETF logoVanguard FTSE All-World ex-US ETFVEU
Market value
1.32M
Weight
0.00%
AUM
95.9B USD
Expense ratio
0.04%
Price / 1D
$85.69+0.82%
Dimensional - Emerging Markets Core Equity 2 ETF logoDimensional - Emerging Markets Core Equity 2 ETFDFEM
Market value
763.82K
Weight
0.01%
AUM
9.49B USD
Expense ratio
0.39%
Price / 1D
$39.93+0.50%
Schwab Emerging Markets Equity ETF logoSchwab Emerging Markets Equity ETFSCHE
Market value
753.14K
Weight
0.01%
AUM
12.89B USD
Expense ratio
0.06%
Price / 1D
$36.97+0.71%
JPMorgan ActiveBuilders Emerging Markets Equity ETF logoJPMorgan ActiveBuilders Emerging Markets Equity ETFJEMA
Market value
595.47K
Weight
0.03%
AUM
1.7B USD
Expense ratio
0.33%
Price / 1D
$62.2959+0.80%
Vanguard Total World Stock ETF logoVanguard Total World Stock ETFVT
Market value
406.94K
Weight
0.00%
AUM
97.9B USD
Expense ratio
0.06%
Price / 1D
$160.77+0.53%
Dimensional - Emerging Core Equity Market ETF logoDimensional - Emerging Core Equity Market ETFDFAE
Market value
385.56K
Weight
0.00%
AUM
10B USD
Expense ratio
0.29%
Price / 1D
$39.49+0.51%

Continue in GoAI

Research 3347.HK

research.disclaimer